Effects of Shenlingbaizhu powder combined with mesalazine in the treatment of ulcerative colitis and the influence of NLRP3 inflammasome

doi:10.12092/j.issn.1009-2501.2018.03.013

Abstract

Abstract:

AIM: To investigate the clinical effect of Shenlingbaizhu powder combined with mesalazine in the treatment of ulcerative colitis (UC) and the influence of Nod-like receptor pyrin domain 3 (NLRP3) inflammasome. METHODS: One hundred patients with UC were randomly divided into control group and observation group, fifty cases in each group. The control group was given mesalazine 1.0 g qid, while the observation group was given Shenlingbaizhu powder 6.0 g tid combined with mesalazine 1.0 g qid. The course of treatment was eight weeks. The clinical efficacy of the two groups was compared; the expression levels of NLRP3, apoptosis-associated speck-like protein containing CARD (ASC) and caspase-1mRNA were detected; The levels of C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), interleukin-1 beta (IL-1β) and interleukin-18 (IL-18) in serum was detected. RESULTS: After treatment, the total effective rate of the clinical symptoms of observation group (86%) was significantly better than that of control group (73%), the difference was statistically significant (P<0.05). The expression of NLRP3, ASC, caspase-1 mRNA in observation group (4.08±0.85, 3.75±0.91, 3.86±0.93) were more lower than those of control group (5.26±0.96, 4.66±0.95, 4.97±0.99), and the difference was statistically significant (P<0.05). The levels of CRP, ESR, IL-1 beta and IL-18 in observation group (6.74±2.45,11.63±4.58,44.27±8.58, 263.37±60.34) were more lower than those of control group (15.32±5.68,18.45±5.12,51.11±9.26, 371.18±61.25), and the difference was statistically significant (P<0.05). CONCLUSION: Shenlingbaizhu powder combined with mesalazine in the treatment of UC has good clinical curative effect, the mechanism may be related with the inhibition of NLRP3 inflammasome and inflammation.

Key words: Shenlingbaizhu powder, ulcerative colitis, curative effect, NLRP3 inflammasome

CLC Number:

R574.62

ZHOU Taomei, YANG Shangwen, WANG Jianbo. Effects of Shenlingbaizhu powder combined with mesalazine in the treatment of ulcerative colitis and the influence of NLRP3 inflammasome[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(3): 319-324.

References

［1］Eugène C. Ulcerative colitis practice guidelines in adults［J］. Clin Res Hepatol Gastroenterol, 2012, 36(2):107-109.
［2］Ye L, Cao Q, Cheng J. Review of inflammatory bowel disease in China［J］. Scient World J, 2013, 2013:296470.
［3］强薇,魏秀芹.活动期溃疡性结肠炎患者凝血指标变化及其临床指导价值［J］.现代仪器与医疗,2017,23(6):65-67.
［4］俞晓燕, 许澄. 美沙拉嗪治疗溃疡性结肠炎的临床疗效分析［J］. 中国初级卫生保健, 2012,26(12):102-103.
［5］翁湘涛, 胡月, 廖柳,等. 参苓白术散加减对比西药治疗溃疡性结肠炎的疗效和安全性Meta分析［J］. 中国实验方剂学杂志, 2017(10):205-210.
［6］De IFM, Franchi L, Araya D, et al. Escherichia coli isolates from inflammatory bowel diseases patients survive in macrophages and activate NLRP3 inflammasome.［J］. Int J Med Microbiol, 2014, 304(3/4):384-392.
［7］许文彬, 陈玉, 张涛,等. NLRP-3炎症小体及CCL-3在溃疡性结肠炎中表达的意义［J］. 中国中西医结合消化杂志, 2016, 24(6):418-421.
［8］中华医学会消化病学分会炎症性肠病学组. 炎症性肠病诊断与治疗的共识意见(2012年·广州)［J］. 胃肠病学, 2012, 51(12):763-781.
［9］Meier J, Sturm A. Current treatment of ulcerative colitis［J］. World J Gastroenterol, 2011,17(27):3204-3212.
［10］韩志宏, 托静美, 王燕平, 等. 康复新液联合美沙拉嗪治疗溃疡性结肠炎疗效观察［J］. 海南医学, 2016,27(7):1147-1149.
［11］周健华, 陈利国, 许青芸,等. 溃疡性结肠炎与血瘀证［J］. 长春中医药大学学报, 2016, 32(3):495-497.
［12］刘翠英, 黄娟, 施旭光. 参苓白术散治疗脾虚泄泻证的研究进展［J］. 江西中医药, 2016, 47(11):68-71.
［13］邹浩. 参苓白术散联合美沙拉嗪治疗脾胃气虚型溃疡性结肠炎疗效［J］. 中国医药科学, 2015(21):74-76.
［14］穆丽萍, 肖明. 参苓白术散治疗溃疡性结肠炎长期应用的疗效与安全性［J］. 辽宁中医杂志, 2016(2):309-311.
［15］Moss AC. Residual inflammation and ulcerative colitis in remission［J］. Gastroenterol Hepatol, 2014, 10(3):181-183.
［16］Scarpa M, Castagliuolo I, Castoro C, et al. Inflammatory colonic carcinogenesis: A review on pathogenesis and immunosurveillance mechanisms in ulcerative colitis［J］. World J Gastroenterol, 2014, 20(22):6774-6785.
［17］刘丹, 周磊. 溃疡性结肠炎患者血小板、C反应蛋白、血沉的临床意义［J］. 中国现代药物应用, 2015(18):13-15.
［18］Christina A, Russo HM, Caroline ES, et al. Caspase-8 as an effector and regulator of NLRP3 inflammasome signaling［J］. J Biol Chem, 2015, 290(33):20167-84.
［19］Kanneganti TD. Inflammatory bowel disease and the NLRP3 inflammasome［J］. New Engl J Med, 2017, 377(7):694.
［20］Aguilera M, Darby T, Melgar S. The complex role of inflammasomes in the pathogenesis of Inflammatory Bowel Diseases - Lessons learned from experimental models.［J］. Cytokine Growth Factor Rev, 2014, 25(6):715-730.
［21］Zhang J, Fu S, Sun S, et al. Inflammasome activation plays an important role in the development of spontaneous colitis［J］. Mucosal Immunol, 2014, 7(5):1139-1150.
［22］矫树华, 刘鹏亮, 温艳惠. 血清C反应蛋白、脂肪酶、白细胞介素1β和细胞间黏附分子1联合检测在急性胰腺炎诊断中的应用价值［J］. 临床肝胆病杂志, 2016(1):131-134.
［23］AI MK, Kazmierczak BI. Distinct contributions of interleukin-1α (IL-1α) and IL-1β to innate immune recognition of Pseudomonas aeruginosa in the lung［J］. Infect Immun, 2014, 82(10):4204.
［24］Arifa RD, Madeira MF, Paula TP, et al. Inflammasome activation is reactive oxygen species dependent and mediates irinotecan-induced mucositis through IL-1β and IL-18 in mice［J］. Am J Pathol, 2014, 184(7):2023-2034.
［25］Esper L, Utsch L, Soriani FM, et al. Regulatory effects of IL-18 on cytokine profiles and development of myocarditis during Trypanosoma cruzi infection［J］. Microbes Infect, 2014, 16(6):481-490.
［26］唐月华, 王小平. 溃疡性结肠炎患者血清 IL-1β和 IL-18的表达及临床意义［J］. 河北医药, 2015(10):1534-1535.

[1]	DENG Li, TIAN Jing. Resveratrol suppresses NLRP3 inflammasome activation in colonic epithelial cells triggered by Escherichia coli O104∶H4 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 167-173.
[2]	WANG Yanhong, PU Junfeng, LI Hongling, FENG Tiexin. Protective effect and mechanism of manganese superoxide dismutase mimic on ulcerative colitis induced by trinitrobenzene sulfonic acid in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(10): 1081-1087.
[3]	ZHENG Weiwei, WANG Jiajia. Effects of Qingchang zhili soup and moxibustion on ulcerative colitis and inflammatory factors [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(2): 198-204.
[4]	ZHANG Wenxi, GAO Wei, ZHAO Jiajia, CAI Qiao, ZHAO Bei, ZHENG Yan. Curative effect of erythromycin in the treatment of ureaplasma mycoplasma pneumonia and its influence on cell subset and liver function [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 194-198.
[5]	LOU Chaosheng, WU Xian, WANG Haibo, ZHANG Yin, YE Lechi. Therapeutic effect and mechanism of Yipi Yangwei decoction in treating ulcerative colitis-related cancerous mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(10): 1088-1096.
[6]	YUAN Shaofei, ZHU Linjia, ZHENG Weie, LIANG Meizhen. Relationship of Syndecan-1 and EGFR expression, K-Ras gene mutations and response to FOLFOX in advanced colorectal carcinoma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 927-932.
[7]	SONG Xiujuan，LIN Yongjian，WANG Lina，XU Huiqin，LIU Xiaoli. Effect of oxiracetam combined with Cistanche yizhi capsule in treating cognitive disorder from leukoaraiosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(2): 184-189.
[8]	WANG Shiqi, HU Huawen, CHEN Xiaomin, WANG Jian, YE Honghua. Effects of different intensities of warfarin on patients with coronary atherosclerotic heart disease complicated with atrial fibrillation: a comparative study [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(12): 1410-1414.
[9]	LI Juan, WANG Yu-lan. Analysis on clinical efficacy in the near future of mesalazine oral combined with enema for mildly to moderately distal ulcerative colitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(8): 907-911.
[10]	ZHAO Xiao-yan. Acyclovir in the treatment of facial paralysis clinical and prognostic analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(6): 670-673.
[11]	TAO Yun, GONG Guo-qing, QIAN Zhi-yu, CHENG Wen-yuan, WANG Xin-hui. Effects of crocetin on ulcerative colitis in rats and the mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(3): 263-270.
[12]	WANG Yan-hong, YANG Xiao-lai, WANG Li, CUI Ming-xia, ZAI Jing, WU Yong-jie. Effects of proanthocyanidins from grape seeds on the antioxidation in the resistance to oxidation and NO comtents [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(1): 47-52.
[13]	ZHANG Rong, WANG Zhi-peng, LIU Li, MEI Qi-bing. Effects of rheum tanguticum polysaccharides on ulcerative colitis induced by TNBS in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(9): 995-998.
[14]	WANG Hao, WU Wan-chun, HAN Zhen, JIN Dao-you, WANG Meng-ya. Effects of psychological stress on pathogenetic condition and rapeutic effect of ulcerative colitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(1): 86-90.
[15]	ZHOU Zhu-cheng, LIU Bao-lin, WU Wei-wei. Effect of luteolin on ulcerative colitis in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(10): 1152-1155.